Bioreactors Market Size

Governments and several pharma companies are investing heavily in research and development activities to introduce next-gen therapeutic solutions such as vaccines, gene therapies, antibiotics, and more to combat infectious diseases including, COVID-19. For instance, the Medical Countermeasures Gov revealed that the Biomedical Advanced Research and Development Authority (BARDA) in collaboration with the National Institute of Allergy and Infectious Disease is concentrating on the development of next-gen medical solutions such as vaccines and therapeutics to protect Americans from public health security threats such as coronaviruses.

Furthermore, in June 2024, the U.S. Department of Health and Human Services announced that BARDA awarded USD 500 million in Project NextGen funding for vaccine clinical trials. The funding is set to execute several Phase 2b clinical trials to evaluate novel vaccines administered as a nasal spray or pill to protect against symptomatic COVID-19. Such moves create profitable opportunities for bioreactor manufacturers, as bioreactor systems are necessary for the chemical reaction process in the developmental and clinical phases.